Akt2 - AKT serine/threonine kinase 2 Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 25233

About Akt2

Primary_assembly 1: 82,883,547-82,933,817 forward strand.mRatBN7.2:CM026974.1

This gene has 4 transcripts (splice variants), 237 orthologues, 5 paralogues and is associated with 31 phenotypes. Biased expression in Muscle (RPKM 265.6), Heart (RPKM 231.4) and 9 other tissues.

Summary

Enables ATP binding activity; protein kinase C binding activity; and protein serine/threonine kinase activity. Involved in several processes, including negative regulation of nitrogen compound metabolic process; positive regulation of glucose import; and positive regulation of nitrogen compound metabolic process. Acts upstream of or within cellular response to Insulin stimulus and positive regulation of sodium ion transport. Located in several cellular components, including insulin-responsive compartment; mitochondrion; and sarcoplasmic reticulum. Used to study high grade glioma and ischemia. Biomarker of colorectal cancer; hepatocellular carcinoma; hypertension; and obesity. Human ortholog(s) of this gene implicated in glucose metabolism disease (multiple); hypoinsulinemic hypoglycemia with hemihypertrophy; and reproductive organ Cancer (multiple). Orthologous to human Akt2 (Akt serine/threonine kinase 2). [provided by Alliance of Genome Resources, Apr 2022]

Akt2 Products (1)

mRNA Protein Name
NM_017093.1 NP_058789.1 RAC-beta serine/threonine-protein kinase

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables ATP binding IDA
IDA: Inferred from direct assay
9880520 RGD
enables protein binding IPI
IPI: Inferred from physical interaction
15684423 RGD
enables protein kinase C binding IPI
IPI: Inferred from physical interaction
7488143 RGD
enables protein serine/threonine kinase activity IDA
IDA: Inferred from direct assay
9880520 RGD
Biological Process GO Annotation Evidence References Source
involved in cellular response to hormone stimulus IEP
IEP: Inferred from expression pattern
15196698 RGD
acts upstream of or within cellular response to insulin stimulus IMP
IMP: Inferred from mutant phenotype
17715136 RGD
involved in cellular response to organic cyclic compound IDA
IDA: Inferred from direct assay
11812651 RGD
involved in negative regulation of RNA splicing IMP
IMP: Inferred from mutant phenotype
19116344 RGD
involved in negative regulation of apoptotic process IMP
IMP: Inferred from mutant phenotype
19084003 RGD
involved in negative regulation of cysteine-type endopeptidase activity involved in apoptotic process IMP
IMP: Inferred from mutant phenotype
18348079 RGD
involved in phosphatidylinositol 3-kinase/protein kinase B signal transduction IMP
IMP: Inferred from mutant phenotype
16469952 RGD
involved in positive regulation of D-glucose import IMP
IMP: Inferred from mutant phenotype
18335029 RGD
involved in positive regulation of cell migration IMP
IMP: Inferred from mutant phenotype
19330838 RGD
involved in positive regulation of gene expression IMP
IMP: Inferred from mutant phenotype
15557754 RGD
involved in positive regulation of nitric oxide biosynthetic process IMP
IMP: Inferred from mutant phenotype
18335029 RGD
involved in positive regulation of peptidyl-serine phosphorylation IMP
IMP: Inferred from mutant phenotype
18348079 RGD
involved in positive regulation of positive chemotaxis IDA
IDA: Inferred from direct assay
19330838 RGD
involved in positive regulation of protein phosphorylation IMP
IMP: Inferred from mutant phenotype
19116344 RGD
involved in positive regulation of signal transduction IMP
IMP: Inferred from mutant phenotype
19084003 RGD
acts upstream of or within positive regulation of sodium ion transport IMP
IMP: Inferred from mutant phenotype
17715136 RGD
involved in positive regulation of transcription by RNA polymerase II IMP
IMP: Inferred from mutant phenotype
16469952 RGD
involved in protein phosphorylation IDA
IDA: Inferred from direct assay
9880520 RGD
involved in response to hypoxia IEP
IEP: Inferred from expression pattern
29676955 RGD
involved in response to insulin IDA
IDA: Inferred from direct assay
15684423 RGD
involved in response to insulin IEP
IEP: Inferred from expression pattern
18335029 RGD
involved in response to muscle activity IEP
IEP: Inferred from expression pattern
11809761 RGD
involved in response to nutrient levels IEP
IEP: Inferred from expression pattern
18094069 RGD
Cellular Component GO Annotation Evidence References Source
located in insulin-responsive compartment IDA
IDA: Inferred from direct assay
9516411 RGD
located in sarcoplasmic reticulum IDA
IDA: Inferred from direct assay
29676955 RGD
located in vesicle IDA
IDA: Inferred from direct assay
9880520 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Akt2 Protein Structure

PH_PKB

PH_PKB: cd01241 (31 - 125)

STKc_PKB_beta

STKc_PKB_beta: cd05595 (170 - 492)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 496 a.a.
Protein Preferred Names Protein Names

RAC-beta serine/threonine-protein kinase

  • AKT2 kinase

  • PKB beta

  • RAC protein kinase beta RAC-PK beta

  • RAC-PK-beta

  • murine thymoma viral (v-akt) oncogene homolog 2

  • protein kinase Akt-2

  • protein kinase B beta

  • thymoma viral proto-oncogene 2

  • v-akt murine thymoma viral oncogene homolog 2

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (2)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-15431 Capivasertib Inhibitor 99.96% Unkown
HY-B0960 Sulfabenzamide 99.68% Unkown
Inhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P99118 Serplulimab Inducer 99.30% Unkown

Clinical Phase

Bioactive Molecules (13)
Cat. No. Product Name Effect
Purity Phase
HY-N0004 Oridonin Inhibitor 99.89% Phase 4
HY-15727 Afuresertib Inhibitor 99.53% Phase 3
HY-15186A Ipatasertib dihydrochloride Inhibitor 99.27% Phase 3
HY-15186C Ipatasertib tosylate Inhibitor / Phase 3
HY-19719 Miransertib Inhibitor 99.32% Phase 2
HY-108232 MK-2206 Inhibitor 99.72% Phase 2
HY-15965 Uprosertib Inhibitor 99.93% Phase 2
HY-19934 Pifusertib Inhibitor 99.81% Phase 2
HY-10358 MK-2206 dihydrochloride Inhibitor 99.99% Phase 1
HY-10249 GSK-690693 Inhibitor 99.03% Phase 1
HY-100018 BAY1125976 Inhibitor 99.52% Phase 1
HY-16071 AT13148 Inhibitor 99.20% Phase 1
HY-137458A Vevorisertib trihydrochloride Inhibitor 99.60% Phase 1

Pre-clinical Phase

Bioactive Molecules (30)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-15186 Ipatasertib Inhibitor 99.88% Yes
HY-10355 AKT inhibitor VIII Inhibitor 98.97% Unkown
HY-10425 Rizavasertib Inhibitor 99.04% Unkown
HY-133120 INY-03-041 Inhibitor 99.74% Unkown
HY-13260 CCT128930 Inhibitor 99.69% Unkown
HY-151504 Engasertib Inhibitor 99.65% Unkown
HY-12059 AT7867 Inhibitor 99.85% Unkown
HY-19934A Pifusertib hydrochloride Inhibitor 99.90% Unkown
HY-19982 AKT-IN-6 Inhibitor 99.08% Unkown
HY-15727A Afuresertib hydrochloride Inhibitor 99.95% Yes
HY-19719A Miransertib hydrochloride Inhibitor 99.74% Yes
HY-50862 Akt1/Akt2-IN-1 Inhibitor 99.30% Unkown
HY-145282 MS170 Inhibitor 98.68% Unkown
HY-12059A AT7867 dihydrochloride Inhibitor 99.73% Unkown
HY-137458 Vevorisertib Inhibitor 98.03% Unkown
HY-133120A INY-03-041 trihydrochloride Inhibitor 99.78% Unkown
HY-132302 Hu7691 Inhibitor 99.91% Unkown
HY-13260A CCT128930 hydrochloride Inhibitor 98.97% Unkown
HY-16666 3CAI Inhibitor 98.32% Unkown
HY-129119 Akt1/Akt2-IN-2 Inhibitor 98.57% Unkown
HY-151613 MS15 Inhibitor / Unkown
HY-126257 AKT-IN-3 Inhibitor 98.12% Unkown
HY-143883 MS143 Degrader 97.8% Unkown
HY-132302A Hu7691 free base Inhibitor / Unkown
HY-145281 MS98 Inhibitor / Unkown
HY-10357 MK-2206 free base Inhibitor / Unkown
HY-138767 AKT-IN-5 Inhibitor / Unkown
HY-143611 AKT-IN-8 Inhibitor / Unkown
HY-15965A Uprosertib hydrochloride Inhibitor / Unkown
HY-16032 Akt1-IN-2 Inhibitor 99.83% Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Akt2 NCBI NCBI:208